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Background: To globally characterize the cancer stroma expression profile of muscle-invasive transitional cell
carcinoma and to discuss the cancer biology as well as biomarker discovery from stroma. Laser capture micro
dissection was used to harvest purified muscle-invasive bladder cancer stromal cells and normal urothelial stromal
cells from 4 paired samples. Two-dimensional liquid chromatography tandem mass spectrometry was used to
identify the proteome expression profile. The differential proteins were further analyzed using bioinformatics tools
and compared with the published literature.
Results: We identified 868/872 commonly expressed proteins and 978 differential proteins from 4 paired cancer
and normal stromal samples using laser capture micro dissection coupled with two-dimensional liquid
chromatography tandem mass spectrometry. 487/491 proteins uniquely expressed in cancer/normal stroma.
Differential proteins were compared with the entire list of the international protein index (IPI), and there were 42/42
gene ontology (GO) terms exhibited as enriched and 8/5 exhibited as depleted in cellular Component, respectively.
Significantly altered pathways between cancer/normal stroma mainly include metabolic pathways, ribosome, focal
adhesion, etc. Finally, descriptive statistics show that the stromal proteins with extremes of PI and MW have the
same probability to be a biomarker.
Conclusions: Based on our results, stromal cells are essential component of the cancer, biomarker discovery and
network based multi target therapy should consider neoplastic cells itself and corresponding stroma as whole one.
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Biomarker panelIntroduction
Despite recent advances in surgical techniques, peri-
operative chemo radiotherapy and the development of
molecularly targeted therapies, muscle-invasive bladder
transitional cell carcinoma (BTCC) is still a major epi-
demiological problem whose incidence continues to rise
each year [1]. The prognosis of muscle-invasive BTCC is
poor and the 5-year disease specific survival after radical
cystectomy remains 50–60% [2]. Though some molecu-
lar pathogenesis studies on invasive bladder carcinoma
have been undertaken successfully on the gene and tran-
scription levels, the carcinogenic mechanism remains to
be elucidated. In this regard, using stroma as a sample* Correspondence: qyxinshengwang@126.com
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reproduction in any medium, provided the ormay be an alterative way to study muscle-invasive BTCC
carcinogenesis. However, there has been no report of
this item.
As one of the solid tumors, muscle-invasive BTCC are
composed of two independent while interactive compo-
nents: the neoplastic epithelial cells and the surrounding
cancer stroma. These two components interactive and in
charge of the cancer biology as a functional whole.
Therefore, when looking for the initiator and the mo-
lecular mechanisms of muscle-invasive BTCC, it has to
be kept in mind that a tumor represents an extensive
cellular network of neoplastic and stromal cells [3]. In
comparison with the cancer cells, stromal cells are much
complicated for stroma contains several types of cells.
These cells include fibroblasts, blood vessels and im-
mune cells as well as some other components. Till now,
it is difficult to separate the stromal component one by
one; however the proteome expression profile represents. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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action of all kinds of stromal cells. Discovery of prote-
ome expression profile that are integral to neoplastic
cells specialized stroma may advance our understanding
of the cancer biology and yield novel biomarkers and
targets for anticancer therapies.
Based on the above research background, we per-
formed comparative proteomics research on stromal
cells from muscle-invasive BTCC. Aimed to enlarge the
coverage of proteome profile and so to analyze the data
from a systematical standpoint, shotgun strategy was
employed. Purified stromal cells were obtained by laser
capture micro dissection and two dimensional liquid
chromatography in conjunction with tandem mass spec-
trometry (2D-LC-MS/MS) for the direct analysis of com-
plex mixtures was used for the construction of
expression profile.
After the construction of expression profile, gene
ontology (GO) analysis was performed and the global
features of the expression profile as well as biomarker
panel discovery were discussed. Aimed to achieve a sys-
tematical description of pathway changes and facilitate
the network-based multi-target therapy as well as bio-
marker discovery, a careful analysis of the pathways in
the Kyoto Encyclopedia of Genes and Genomes (KEGG)
database was conducted with the Array Track software.
Methods
Patients and tissue samples
A total of 4 paired muscle-invasive BTCC and normal
urothelial samples (confirmed by two individual patho-
logical diagnoses) were obtained from patients treated at
the Affiliated Hospital of Medical College Qingdao Uni-
versity immediately after radical cystectomy due to pri-
mary invasive bladder cancer. The cancer and the
adjacent microscopically normal urothelium (away from
5 cm) samples were rinsed in sterile PBS and snap fro-
zen in liquid nitrogen within 30 min of removal. The re-
search protocol was approved by the Institutional
Review Board and informed consent was obtained from
patients.
Laser capture micro dissection
Eight-micrometer sections of freshly prepared tissues
were stained with hematoxylin and eosin (H&E) using
standard manufacturer’s protocols with minor modifica-
tions. Once air-dried, the sections were micro dissected
with a Leica AS LMD Laser Capture Micro dissection
System (Sunnyvale, CA). To avoid the degradation of
protein, we captured the cells within 120 min each cap.
Laser capture micro dissected cells were dissolved in
lysis buffer (95 mM urea, 4% CHAPS, 40 mM Tris,
65 mM DTT). Samples were solubilized via sonication
using 20 second bursts, followed by ice cooling(20 seconds), in a process that was repeated 5 times.
After that, the crude tissue extracts were centrifuged for
45 min at 15,000 rpm to remove the undissolved pellets.
All samples were stored at −80°C until use.
Digestion of protein mixture and 2D-LC-MS/MS
Samples prepared by LCM technology were deposited in
precipitation solution (50% acetone/50% ethanol/0.1%
acetic acid, sample volume: precipitation solution vol-
ume = 1:5) for at least 12 h at −20°C. The pellets were
washed by 100% acetone and 70% ethanol, then redis-
solved in 6 mM guanidine-HCl/100 mM Tris (pH 8.3),
and the concentrations were measured by Bio-Rad pro-
tein assay kit. Next, 200 μg of soluble proteins were
reduced with DTT (final concentration 20 mM) and
subsequently alkylated with IAA (final concentration
40 mM). After desalting and removal of toludine blue by
ultrafiltration with Microcon-10, the protein mixture
was incubated overnight at 37°C with trypsin (trypsin:
protein mixture = 1:30 w/w; Promega). Two-dimensional
high-performance LC separations were performed on a
ProteomeX work station (Thermo Finnigan) equipped
with two capillary LC pumps. The flow rate of both salt
and 4 analytical pumps was at 120 μl/min and was about
1.5 μl/min after split. Nine different salt concentration
ranges from 0, 25, 50, 75, 100, 150, 200, 400, and
800 mM ammonium chloride were used for step gradi-
ent. The mobile phases used for reverse phase were: A,
0.1% formic acid in water, pH 3.0; B, 0.1% formic acid in
acetonitrile. The Finnigan LTQ linear ion trap mass
spectrometer was used for the MS/MS experiment with
an ion transfer capillary of 160°C and Spray voltage of
3.0 kV. Normalized collision energy was 35.0%. After ac-
quisition of full-scan mass spectra, 10 MS/MS scans
were acquired for the next 10 most intense ions using
dynamic exclusion. Peptides and proteins were identified
using Sequest software (Thermo Finnigan), which uses
the MS and MS/MS spectra of peptide ions to search
against the publicly available IPI (International Protein
Index) database. The spectra for singly charged peptides
with a cross-correlation score to a tryptic peptide
(Xcorrs) greater than 1.9, the spectra for doubly charged
tryptic peptides with Xcorrs of at least 2.2, and the spec-
tra for triply charged tryptic peptides with Xcorrs above
3.75 were accepted as correctly identified according to
Sequest software. For all the spectra analyzed, ΔCn
values were above o.1.
GO enrichment/depletion analysis
To take an overview of our comparative proteomics ana-
lysis, the cancer/normal stroma specific proteins were
categorized as to GO assignments (www.geneontology.
org), and GOfact software was used to find statistically
over- or under-represented GO categories in biological
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dataset [4]. For enrichment analysis, a test dataset
(which is our identified proteins) and a reference set of
GO annotation for the complete human proteome were
in need. As per instructions on the GOfact webpage, the
custom GO annotation for the reference set (of whole
IPI human dataset) was created by extracting the GO
annotations available for Human IPI IDs from EBI GOA
Human 80.0 release. The analysis was done using “hyper
geometric test”; the GO terms with P < 0.05 or P < 0.01
were selected as enriched/depleted or significantly
enriched/depleted.Pathway analysis
To take an overview of our comparative proteomics ana-
lysis, the differential proteins were categorized first. The
proteins uniquely expressed in cancer or normal stroma
were considered as differential expressed. Next, the IPI
names of the differentially expressed proteins were con-
verted to SWISS-PROT names for SWISS-PROT was a
protein sequence database of low redundancy with high
levels of annotation. Array Track software was used for
pathway analysis. Array Track offers a simple query
interface to retrieve information about human protein
expression profile, and provides direct connections to
related metabolic and regulatory pathways available from
Kyoto Encyclopedia of Genes and Genomes (KEGG) [5].
Most of all, Array Track software can analyze expression
profile without the consideration of differential abun-
dant. For statistical analysis, a P value for pathway en-
richment was obtained using the hyper geometric test
and P <0.05 was considered statistically significant.Evidence based biomarker exploration
The proteins that located in KEGG pathways by Array
Track were defined as potential biomarkers and the
basic physical chemistry of these proteins were further
discussed. Descriptive Statistics was used for calculate
the distribution of the data. Interquartile-range (IQR)
was used to give the basic characteristic of the variability
skewness distribution data. Categorical variables were
expressed as a frequency and were compared by chi-Figure 1 Harvest the cancer stromal vasculature by LCM. (a) Before LCsquare. All analysis was performed with SPSSW, version
16.0 and P < 0.05 was considered statistically significant.
Results
Purify of the cells
Approximately 500, 000 shoots of cancer stromal cells
and normal stromal cells from each sample were micro
dissected and stored on micro dissection caps at −80°C
until lysed. Each cell population was determined to be
98% homogeneous by microscopic visualization of the
captured stroma. Figure 1 shows the precision of LCM
by a representative harvest of blood vessels which is one
of the cancer stromal components.
Identification of the proteins
We respectively identified 998, 991, 957, 1086 proteins
from the 4 cancer stromal samples. Among them, 868
proteins commonly expressed in 4 cancer stromal sam-
ples and defined as the overall expression profile of can-
cer stroma. In parallel, 982; 964; 1022; 979 proteins
respectively identified from the 4 normal stromal sam-
ples. After data match, 872 proteins commonly
expressed in 4 normal stromal samples and defined as
overall expression profile of normal stroma. The pro-
teins uniquely detected in cancer versus normal stroma
were defined as differentially expressed, vice versa. After
comparison, 381 proteins commonly identified in cancer
and normal stroma, 978 proteins showed differentially
expressed between cancer and normal stroma. To obtain
global description of the biological characteristic of inva-
sive bladder cancer stroma, we only analyzed the 978
differentially expressed proteins through comparison of
cancer versus normal stromal samples (487 proteins
uniquely expressed in cancer stroma and 491 proteins
uniquely expressed in normal stroma). The smallest and
largest molecular weight (MW) values observed in dif-
ferential proteins were 6.78 and 986.90 kDa, and the
proteins were distributed across a wide isoelectric point
(PI) range (3.67-11.98).
GO and GO enrichment/depletion analysis
After analysis, 347 and 319 of the proteins that specific























































































































































Figure 2 Enriched/depleted GO celluar component terms for the set of cancer/normal cells specific proteins. Purple/red indicates
enriched terms in normal/cancer stromal cells; light blue/dark green indicates depleted terms in normal/cancer stromal cells. Underline indicates
significantly enriched/depleted terms.
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the IPI (IPI_Human, versions 3.53, 219486 entries for
30786 proteins), there were 42 GO cellular component
terms exhibited as enriched and 8 terms exhibited as
depleted in cancer stroma. In parallel with this, however,
there were 42 terms exhibited as enriched and 5 exhib-
ited as depleted in normal stroma. Figure 2 showed en-
richment/depletion analysis of cellular component. The
enriched GO cellular component terms mainly include
protein complex, cytosol, macromolecular complex,
mitchondrion, nuclear part, ribonucleoprotein complex,
cytoskeleton, golgi apparatus, ribosome, etc.
Significant pathways and identification of
potential biomarkers
After conversion, 754 of the 978 differentially expressed
proteins with SwissProAcc numbers and were analyzed
by Array Track software. After analysis, 409 proteins
located at the well-known biological KEGG pathways
and defined as potential biomarkers. The significantFigure 3 Representative KEGG pathway change of Endocytosis. Red inaltered pathways mainly include metabolic pathways,
spliceosome, regulation of actin cytoskeleton, ribosome,
focal adhesion, Endocytosis, oxidative phosphorylation,
etc. Figure 3 showed a typical changed KEGG pathway.
Table 1 lists the major altered pathways that include at
least 10 differential proteins as well as the proteins spe-
cific expressed in cancer stroma and located at meta-
bolic pathways.
Evidence based biomarker exploration
Array Track defined a total of 409 proteins as potential
biomarkers. Figure 4 and Figure 5 show the distribution
of PI and MW about the potential biomarkers as well as
the skewness distribution of the data. When subdivide
the data by PI equal 9 and MW equal 100 kDa, the IQR
was 1.70 for PI ≤ 9 and 1.18 for PI>9, 33.28 for MW ≤
100 and 112.07 for MW>100, respectively. Though the
data that PI ≤ 8 and 8<PI ≤10 looked like normal distri-
bution, the pseudomorphism was see through by de-
scriptive statistics. Chi-square test showed that thedicate the differential proteins located in KEGG pathway.
Table 1 Major altered pathways that include at least 10 differentially expressed proteins, underline indicates the
protein specific expressed in cancer stroma
Pathway Gene name
Metabolic pathways ACAA1, ACADSB, ACO2, ACOX1, ACSL5, ACSM1, ACSM3, ADH1B, ADSS, AK2, AKR1B10, ALDH1B1,
ALDH4A1, APIP, APRT, ASAH1, ATIC, ATP5I, ATP6V1E1, BCKDHA, BCKDHB, CAT, CBS, CHPF, COMT,
COX17, COX5B, CS, CYC1, CYP19A1, DAD1, DBT, DDOST, DGKI, DLAT, DLD, DLST, DUT, FASN,
FH, G6PD, GANAB, GNPDA1, GOT2, GRHPR, HADH, HADHB, HIBADH, HK1, HMGCL, HMGCS2,
HSD17B4, IDH1, IMPDH2, ITPA, ITPKA, LAP3, MAT2A, NANS, NDUFA10, NDUFA4, NDUFA8,
NDUFS4, NDUFS6, NFKB1, NME2, NOS3, OGDH, Cav-1, PAICS, PCK2, PDXK, PFKP, PGD, PGM2, PHPT1,
PNPO, POLR2D, PRDX6, SDHB, SPTLC1, SUCLG2, TYMP, UGDH, UQCRB, UQCRC1
Spliceosome ACIN1, BCAS2, CRNKL1, HNRNPA1, HSPA2, HSPA6, NHP2L1, PUF60, RBM8A, RBMX, SF3A3, SF3B1,
SF3B2, SFRS13A, SFRS2, SFRS3, SFRS4, SFRS5, SFRS9, SNRNP200, SNRPB, SNRPC, SNRPD3, SNRPF,
SNRPG, TRA2B, U2AF2
Regulation of actin cytoskeleton ARPC1B, ARPC2, ARPC3, ARPC5, CDC42, CFL2, CRK, ENAH, IQGAP3, ITGA5, ITGA6, ITGAV, ITGB1,
ITGB4, MYH14, MYLK, PIK3CB, ROCK2, RRAS2, SSH1, SSH3, WASF2
Ribosome RPL18, RPL19, RPL22, RPL23, RPL23A, RPL31, RPL38, RPL5, RPL7A, RPL9, RPLP0, RPLP1, RPS10, RPS17,
RPS20, RPS25, RPS4X, RPS7
Focal adhesion CDC42, COL3A1, COL4A2, CRK, CTNNB1, FLNC, FLT1, ITGA5, ITGA6, ITGAV, ITGB1, ITGB4, MYLK, PIK3CB,
RAP1B, ROCK2, TNC, TNXB, VTN, VWF
Proteasome PSMA3, PSMA4, PSMA5, PSMA7, PSMB2, PSMB7, PSMC1, PSMC2, PSMC4, PSMC6, PSMD2,
PSMD7, PSME2
Endocytosis ACAP2, ARFGAP2, CDC42, CHMP5, CLTA, CLTB, DNM2, EEA1, EHD1, EHD2, EHD4, EPN1, FLT1,
HLA-C, HSPA2, HSPA6, PDCD6IP, RAB11B, RAB11FIP1, VTA1
Huntington's disease CASP8, CLTA, CLTB, COX5B, COX7A2, CYC1, CYCS, DCTN1, NDUFA10, NDUFA4, NDUFA8, NDUFS4,
NDUFS6, POLR2D, SDHB, SOD1, TAF4, UQCRB, UQCRC1
Alzheimer's disease ADAM10, APOE, ATP2A3, CAPN1, CASP8, COX5B, COX7A2, CYC1, CYCS, LRP1, NDUFA10, NDUFA4,
NDUFA8, NDUFS4, NDUFS6, PPP3R1, SDHB, UQCRB, UQCRC1
Oxidative phosphorylation ATP5I, ATP6V1E1, COX17, COX5B, COX7A2, CYC1, NDUFA10, NDUFA4, NDUFA8, NDUFS4, NDUFS6,
PPA1, SDHB, UQCRB, UQCRC1
Systemic lupus erythematosus C8G, C9, CTSG, ELANE, H2AFV, H2AFY, HIST1H2AA, HIST1H2BA, HIST2H3A, HIST2H3C, HIST2H3D,
HLA-DRB1, SNRPB, SNRPD3, SSB
Valine, leucine and isoleucine degradation ACAA1, ACADSB, ALDH1B1, BCKDHA, BCKDHB, DBT, DLD, HADH, HADHB, HIBADH, HMGCL, HMGCS2
Pathogenic Escherichia coli infection ARPC1B, ARPC2, ARPC3, ARPC5, CDC42, CDH1, CTNNB1, CTTN, HCLS1, ITGB1, ROCK2, TUBB3
ECM-receptor interaction AGRN, COL3A1, COL4A2, ITGA5, ITGA6, ITGAV, ITGB1, ITGB4, TNC, TNXB, VTN, VWF
Complement and coagulation cascades C4BPA, C8G, C9, CFH, CFI, KNG1, PLG, SERPINC1, SERPING1, VWF























Figure 4 Distribution of PI about the potential biomarkers. Turning curve shows the global skewness distribution of the data. The data that
PI≤ 8 (Skewness = 0.330 SE = 0.146; Kurtosis = 0.425, SE = 0.292, P<0.05) and 8<PI≤ 10 (Skewness = 0.211, SE = 0.240; Kurtosis = 0.198, SE = 0.476,
P<0.05) also showed skewed distribution though looks like normal distribution.























Figure 5 Turning curve shows the global skewness distribution MW about the potential biomarkers.
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probability to be a biomarker (Table 2).
Discussion
Tissue specific proteomics data can only be generated if
the sample investigated consists of homogeneous cell
population. Then as the initial step of our study about
cancer stroma, LCM is employed to harvest purified
stromal cells. After comparison, 978 proteins showed
differentially expressed between cancer and normal sam-
ple. Up till now, our outcome present the largest stromal
proteome expression profile of muscle-invasive BTCC by
compared with the published literatures. A significant
number of differential proteins have been previously
reported functional in carcinogenesis. Elevated expres-
sion of ITGB1 and activation of ITGB1-coupled signal-
ing have been implicated in the induction and
propagation of a wide variety of human cancers and tar-
geted disruption of ITGB1 has shown to inhibit both the
initiation and maintenance of mammary cancer growth
in vivo [6]. ROCK2 was overexpressed in hepatocellular
carcinoma, and down-regulation of ROCK2 can suppress
cancer metastasis and progression [7]. TNC was an
extracellular matrix glycoprotein which was frequently
up-regulated in a variety of cancers and has been impli-
cated in the modulation of cell migration, proliferation,
invasion and angiogenesis [8]. Other examples are
TNXB, ARPC2, etc. [9,10]. Though present study offer aTable 2 Chi-square test showed that the proteins had
same chance to be a biomarker and irrespective
with the PI, MW
Variable Protein number (n = 754)
Biomarker (n = 409) Non (n= 345) P value
PI ≤9 336 297 >0.05
>9 73 48
MW (kDa) ≤100 326 279 >0.05
>100 or<10 83 66list of candidate biomarkers, the results were derived
from a small number of cases and should thus be con-
sidered preliminary. Aimed to avoid this disadvantage
and enhance the scientificalness of the article, we further
analyzed the expression profile by GO and pathway
analysis.
Proteomics characterization of individual subcellular
fundamental patterns (e.g., organelles) can provide valu-
able information regarding their function in cancer [11].
In addition, this type of approach circumvents analytical
issues associated with the complexity of the entire prote-
ome and represents a tractable method for determining
the proteome of a given subcellular structure. At a con-
ceptual level, the most complete model of subcellular
patterns is probably the GO cellular component ontol-
ogy. We can imagine easily associating GO terms with
most fundamental patterns by checking which organelle
markers are assigned to each. Compared with all human
proteins deposited on IPI, the GO enrichment/depletion
of the subcellular pattern mean the proteins in these cat-
egories are over/under presented in this profile and re-
flect the biologically specific categories of these data. By
this way, shotgun strategy can understand carcinogenesis
by subcellular level even without consideration of differ-
entially abundant. As shown in Figure 2, our observation
indicated that the global over/under represented terms
in subcellular pattern of invasive bladder cancer stroma
and normal urothelial stroma was quite consistent. Be-
sides the global consistence, the proteins belong to each
term were completely different. The different proteins
clustered in each same term reflect different molecular
networks can maintain the same basic subcellular pat-
tern; meanwhile the dysfunctions of specific subcellular
pattern may lead to carcinogenesis. From Figure 2, the
main dysfunctional cellular components in our expres-
sion profile include mitochondrion, golgi apparatus,
ribosome, etc. Many lines of evidence suggest that mito-
chondrion has a central role in carcinogenesis [12]. An
altered ribosome could alter the mRNA pool that is
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oncoproteins or decreasing the translation of cancer sup-
pressing proteins [13]. Golgi apparatus is the central hub
for protein sorting and lipid metabolism in the secretory
pathway. Despite major advances in elucidating its molecu-
lar biology in carcinogenesis, the fundamental question of
how the morphogenesis of this organelle is organized on a
system level has remained elusive [14]. Though our out-
come can provide candidate subcellular pattern for further
analysis in muscle-invasvie BTCC stromal study, there are
a number of significant challenges remain. Primarily
related to the complexity of proteomes, such as the over-
lapping physical properties of organelles, some proteins
may be present in multiple subcellular locations, etc. Major
breakthrough must rely on methodological improvements
and extensively cooperation.
Cancer is now appreciated as a disease involving dys-
function of multiple biological pathways [15]. Under-
standing of changes through a proteomics pathway
approach can facilitate not only biomarker discovery but
also network based multi target therapy. The differential
proteins in our practice mainly located at focal adhesion,
metabolic pathways, etc. Focal adhesions have emerged
as an important therapeutic target in cancer and focal
adhesion protein specific siRNAs have been assessed in
several different human cancer cell lines. Although siR-
NAs seem to be relatively efficient in suppressing focal
adhesion protein expression, it does not induce a com-
mon set of phenotypes in nude mice. This fact indicates
that the cancer stroma may play a compensatory role in
governing phenotypic responses on loss of focal adhe-
sion protein expression [16]. Alterations in focal adhe-
sion are among the most consistent hallmarks of cancer,
while the change of metabolic pathway in stroma offered
great thinking space about cancer research. For a long
time, metabolic research, limited to cancer cells them-
selves and called “Warburg effect”. Recently, this kind of
traditional view is questioned and has the tendency of
substituted by “the reverse Warburg effect.” In this new
theory, aggressive cancer cells are “parasites” that use
oxidative stress as a “weapon” to extract nutrients from
surrounding stromal cells. Oxidative stress in stromal
cells induces the autophagic destruction of mitochondria
by mitophagy. Then, stromal cells are forced to undergo
aerobic glycolysis, and produce energy-rich nutrients to
“feed” cancer cells, thus to construct the so-called stro-
mal–epithelial metabolic coupling [17]. As shown in
Table 1, 86 differential proteins located at metabolic
related pathways, this fact stress the importance of can-
cer researches aimed on stromal metabolism. These
pathway changes stresses that stromal cells are essential
component of the cancer, and network based multi tar-
get therapy should consider neoplastic cells themselves
and corresponding stroma.Another contribution of pathway analysis is the pres-
entation of candidate biomarkers. Take the metabolic
pathways mentioned previously that not only maintain
the primary function of stromal cells but also consist of
the “hot-spots” in cancer research as examples. 86 pro-
teins located at the well-known KEGG metabolic path-
ways, 60 proteins uniquely expressed in cancer stromal
sample and the remains uniquely expressed in normal
stromal sample. Although quantitative information can-
not be obtained, specific expressed proteins mean either
the proteins only expressed in one tissue or the expres-
sion of protein exist significant difference based on same
sample amounts. Nowadays, the notion of biomarker
panel that composed by the combination of independ-
ent, complementary markers has been generally recog-
nized [18]. Based on the former description, we can
primarily conclude the proteins as listed in Table 1
might be effective candidates for the biomarker panel re-
search. Besides the few numbers of proteins in these
pathways that have been reported in previous literatures,
most of them are first present in muscle-invasive BTCC
research. Enzyme fatty acid synthase (FASN) that shows
cancer specifically expressed in our practice is a key
metabolic enzyme in energy homeostasis and has been
found up-regulated in different malignant tumors. Sev-
eral small molecule inhibitors of FASN have now been
described or in development for therapeutic use [19].
The roles of these proteins in the BTCC biology deserve
further investigation.
In our practice, the largest MW values observed in dif-
ferential proteins was 986.90 kDa, and the proteins were
distributed across a wide PI range of 3.67 to 11.95. 409
proteins were defined as potential biomarkers by path-
way analysis include 73 proteins that PI>9 and 83 pro-
teins that MW>100 kDa or<10 kDa. Further analysis
shown these proteins have the same probability to be a
biomarker as common proteins. Based on these data,
cancer stroma can be the ideal source of biomarkers and
the proteins with extremes of PI and MW should not be
neglected in cancer research. Though the present study
performs comparative proteomics analysis of purified
muscle-invasive BTCC and corresponding stroma, the
number of differential proteins was too much to be vali-
dated. Then we are conceiving of gel-based techniques
to offer complementary information and to decrease the
scope of candidate biomarkers. Aimed to guide select-
ively gel excision in 2-DE technology, we performed evi-
dence based biomarker exploration. For skewness
distribution data the IQR is often the preferred descriptive
statistics. After divided the data by the detection range of
routine 2-DE, the IQR is 1.70 for PI≤ 9 and 1.18 for PI>9,
33.28 for MW≤ 100 and 112.07 for MW>100, respectively.
Though the data that PI≤ 8, 8<PI≤ 10 looked like normal
distribution, the pseudomorphism was see through by
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8<PI≤ 10 have skewness distribution, they show tendency
that biomarkers centered a range of 5 to 8 and 8–10 in
the first dimension of the gel. As to the distribution of
MW, descriptive statistics can not find some regularity.
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